Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 July 2021 | Story Dr Nitha Ramnath

Prof Francis Petersen, Rector and Vice-Chancellor of the University of Free State, South Africa, invites us to rethink our relationship with the world in a series of ‘Courageous Conversations’ on the theme of ‘The Global Citizen’. Prof Petersen argues that COVID-19 has been a powerful ‘disruptor’ – it was a stark reminder of the need to rethink our identity, of where we belong, our ‘normative’ view of citizenship – if we want to secure long-term survival of our civilisation and the environments that support it.

Global citizenship and the Sustainable Development Goals – 30 July 2021, 13:00 SAST

Join us for the next Courageous Conversation in the Global Citizen series when Prof Petersen will welcome eminent economist, professor at Columbia University, Director of its Earth Institute, and global leader on sustainability, Prof Jeff Sachs.
 
In 2015, almost all countries signed up to the UN Sustainable Development Goals (SDG). This commitment marked an international solidarity of virtually all countries to work towards the betterment and development of every person on earth. Then COVID-19 struck. Not only did the crisis result in a retrogression of successes registered in achieving the SDG, most notably in the reduction of global poverty, but it also exposed global power disparities.
 
In this session, Prof Sachs will discuss global citizenship and the SDGs in the context of recovery from the COVID-19 pandemic, including what an equitable recovery would mean for countries around the world, and will make reference to the 75th anniversary of the Universal Declaration of Human Rights.

Click Here to RSVP

 
More about our guest

Prof Sachs is widely recognised for addressing complex global challenges such as debt crises, hyperinflation, the control of AIDS, malaria, poverty, and climate change, among a myriad of others.

Sachs serves as the Director of the Center for Sustainable Development at Columbia University. He is President of the UN Sustainable Development Solutions Network, a commissioner of the UN Broadband Commission for Development, and an SDG advocate for UN Secretary General, Antonio Guterres. From 2001 to 2018, Sachs served as Special Adviser to UN Secretaries-General Kofi Annan (2001-2007), Ban Ki-moon (2008-2016), and António Guterres (2017-2018). 


A world-renowned economics professor, bestselling author, innovative educator, and global leader in sustainable development, Sachs was the co-recipient of the 2015 Blue Planet Prize, the leading global prize for environmental leadership. He has twice been named among Time Magazine’s 100 most influential world leaders and has received 34 honorary degrees. A survey by The Economist ranked Sachs as among the three most influential living economists.
 

The Global Citizen Courageous Conversations series

In partnership with the South African Chamber of Commerce based in the United Kingdom, the Global Citizen Courageous Conversations series that was launched on 26 May 2021, brings together powerful voices from public life, intellectuals, public interest and business leaders, academics, naturalists, religious leaders, astrophysicists, economists, ecologists, and others.

Eminent South African business leader, Prof Bonang Mohale, joined Prof Petersen for our first Courageous Conversation on 17 June 2021 to unwrap the role that universities can play in creating a ‘global citizen’ mindset to effect material change in a constantly evolving and turbulent international world.  

If you missed our previous Global Citizen Courageous Conversations, you can watch the replay on YouTube, or visit the South African Chamber of Commerce website for the recordings. 



News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept